Accession NumberDB04958

Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monotclonal antibody, LL2 (EPB-2). Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as lupus (SLE).

Protein structureDb04958
Related Articles
Protein chemical formulaNot Available
Protein average weightNot Available
SequencesNot Available
anti-CD22 IgG
humanised anti-CD22 antibody
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
LymphoCideNot Available
Brand mixturesNot Available
CAS number205923-57-5

Investigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.

Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action

Epratuzumab is a recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. It binds with high specificity to normal B-cells and B-cell tumors at the third Ig-like domain of CD22. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).

TargetKindPharmacological actionActionsOrganismUniProt ID
B-cell receptor CD22ProteinunknownNot AvailableHumanP20273 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Drug Interactions
DrugInteractionDrug group
BelimumabThe risk or severity of adverse effects can be increased when Epratuzumab is combined with Belimumab.Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Epratuzumab.Investigational
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Epratuzumab.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Epratuzumab.Investigational
RindopepimutThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Epratuzumab.Investigational
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Epratuzumab.Investigational
Food InteractionsNot Available
Synthesis ReferenceNot Available
General References
  1. Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL, Engert A, Coiffier B, Hoelzer DF, Wegener WA, Teoh NK, Goldenberg DM, Lister TA: Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol. 2006 Aug 20;24(24):3880-6. Epub 2006 Jul 24. [PubMed:16864854 ]
  2. Steinfeld SD, Youinou P: Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases. Expert Opin Biol Ther. 2006 Sep;6(9):943-9. [PubMed:16918261 ]
  3. Goldenberg DM: Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther. 2006 Oct;6(10):1341-53. [PubMed:17069520 ]
  4. Dorner T, Goldenberg DM: Targeting CD22 as a strategy for treating systemic autoimmune diseases. Ther Clin Risk Manag. 2007 Oct;3(5):953-9. [PubMed:18473018 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
1CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
1TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)1
1, 2Active Not RecruitingTreatmentRecurrent Childhood Acute Lymphoblastic Leukemia1
1, 2CompletedTreatmentB-Cell NHL / NHL / Non-Hodgkin's Lymphoma (NHL)1
1, 2CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
1, 2Unknown StatusTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1, 2Unknown StatusTreatmentRecurrent or Refractory B Cell Acute Lymphoblastic Leukaemia1
2Active Not RecruitingTreatmentLeukemias1
2CompletedTreatmentMalignant Lymphomas2
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentSystemic Lupus Erythematosus (SLE)4
2RecruitingTreatmentB ALL / CD22+ Expression / Refractory B-ALL1
2TerminatedTreatmentLeukemias / Pediatric Cancer1
2TerminatedTreatmentLupus Erythematosus, Systemic1
2TerminatedTreatmentWaldenstrom's Macroglobulinemia (WM)1
2Unknown StatusTreatmentMalignant Lymphomas1
3CompletedTreatmentSystemic Lupus Erythematosus (SLE)3
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3TerminatedTreatmentSystemic Lupus Erythematosus (SLE)2
3Unknown StatusTreatmentMalignant Lymphomas1
3WithdrawnTreatmentSystemic Lupus Erythematosus (SLE)1
Not AvailableCompletedNot AvailableLymphomas: Non-Hodgkin / Lymphomas: Non-Hodgkin Cutaneous Lymphoma / Lymphomas: Non-Hodgkin Diffuse Large B-Cell / Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell / Lymphomas: Non-Hodgkin Mantle Cell / Lymphomas: Non-Hodgkin Marginal Zone / Lymphomas: Non-Hodgkin Peripheral T-Cell / Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia / Non-Hodgkin's Lymphoma (NHL)1
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Experimental PropertiesNot Available
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available


Pharmacological action
General Function:
Carbohydrate binding
Specific Function:
Mediates B-cell B-cell interactions. May be involved in the localization of B-cells in lymphoid tissues. Binds sialylated glycoproteins; one of which is CD45. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site can be masked by cis interactions with sialic acids on the same cell surface. Upon ligand induced tyrosine phosphorylation in the immune response seems...
Gene Name:
Uniprot ID:
Molecular Weight:
95347.07 Da
  1. Steinfeld SD, Youinou P: Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases. Expert Opin Biol Ther. 2006 Sep;6(9):943-9. [PubMed:16918261 ]
  2. Leonard JP, Goldenberg DM: Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene. 2007 May 28;26(25):3704-13. [PubMed:17530024 ]
  3. Carnahan J, Stein R, Qu Z, Hess K, Cesano A, Hansen HJ, Goldenberg DM: Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol. 2007 Feb;44(6):1331-41. Epub 2006 Jun 30. [PubMed:16814387 ]
Drug created on October 21, 2007 16:23 / Updated on August 17, 2016 12:24